Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma

NCT03665441 is registered in ClinicalTrials.gov with ERYtech Pharma as lead sponsor.

NCT NCT03665441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03665441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
Lead sponsor
ERYtech Pharma
Phase
Phase 3
Overall status
Completed
Start date
September 15, 2018
Completion date
January 18, 2022
Enrollment
512 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma